Prexasertib (LY2606368)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Prexasertib (LY2606368), covering 2025-02-07 to 2025-02-07. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors [Phase 1]